Health

ADHD Treatment: What Works

Evidence-based ADHD treatments ranked by effect size - stimulants, non-stimulants, behavioural therapy, exercise, and what the research actually supports.

For project work, advisory, or technical questions, send a concise note.

Share what you're working on and what success looks like. I read every message and respond within a few days.

ADHD treatment has a stronger evidence base than most psychiatric conditions. The data are clear on what works, what helps as an adjunct, and what does not move the needle. This article summarises the treatment hierarchy as presented in Barkley's ADHD handbook (4th edition, 2024), drawing on hundreds of randomised controlled trials and the landmark MTA study.

The Treatment Hierarchy

Barkley's framework is straightforward: medication is first-line for moderate-to-severe ADHD, combined treatment adds value for quality of life and comorbidities, and behavioural interventions alone are less effective for core ADHD symptoms than medication alone.

This is not a philosophical position. It is what the data show.

Stimulant Medications

Stimulants remain the gold standard. They have the largest evidence base and the strongest effect sizes of any ADHD intervention.

Non-Stimulant Medications

For individuals who do not respond to stimulants (approximately 30%), cannot tolerate side effects, or have contraindications, several non-stimulant options exist. They are generally less effective than stimulants but serve important roles.

The MTA Study

The NIMH Multimodal Treatment Study of ADHD (MTA, 1999) is the largest and most influential ADHD treatment trial. Its findings shaped current treatment guidelines:

  • Medication alone produced significant ADHD symptom reduction, superior to behavioural treatment alone.
  • Behavioural treatment alone produced moderate improvement.
  • Combined treatment (medication plus behavioural) was best for parenting satisfaction, comorbid anxiety, and allowed lower stimulant doses.
  • Community care (treatment as usual) was the least effective.

The key insight: for core ADHD symptoms, medication had the most impact. Combined treatment added value primarily for comorbidities and family functioning, not for ADHD symptoms themselves.

Behavioural Interventions

Behavioural approaches do not replace medication for moderate-to-severe ADHD, but they address domains that medication does not fully reach.

Special Populations

Treatment responses vary across populations. In preschool children (studied in the PATS trial), stimulants are effective but produce higher side effect rates. Lower doses are recommended (2.5-7.5 mg methylphenidate IR three times daily), and emotional side effects - crying, irritability - are more common than in older children.

In individuals with comorbid autism spectrum disorder, the comorbidity rate with ADHD is 41-78%. Response rates to stimulants are lower, side effects are more frequent, and careful titration is required. Stimulants treat the ADHD symptoms but do not address core ASD features.

For tic disorders, the previous absolute contraindication to stimulants has been relaxed. When tics are moderate and ADHD is severe, stimulants may be used with monitoring. Guanfacine and clonidine may help both conditions simultaneously.

For epilepsy comorbidity, methylphenidate has been studied and does not increase seizure frequency, though close monitoring is warranted if epilepsy is poorly controlled.

What the Numbers Say

The overall treatment picture, distilled:

  • 65-75% respond to the first stimulant tried
  • 80-90% respond when a second stimulant class is trialled
  • 30% show partial or non-response to stimulants and need alternative approaches
  • 48% of children with ADHD receive any treatment at all (NHANES data)
  • Placebo response averages 13%

That last statistic - only 48% receiving treatment - is arguably the biggest problem in ADHD care. The treatments work. The gap is in access and diagnosis, not in evidence.

Treatment Principles

Barkley's treatment principles, summarised:

  1. Medication is first-line for moderate-to-severe ADHD.
  2. Combined treatment adds value for quality of life, comorbidities, and family functioning.
  3. Treatment must be individualised based on age, severity, comorbid conditions, family preferences, and side effect profiles.
  4. Regular monitoring is essential - follow-up visits, growth charting, symptom tracking.
  5. Psychoeducation is critical. Families who understand ADHD as a neurodevelopmental condition have better outcomes than those who view it as a behavioural problem.
  6. Comorbidities need separate attention. ODD, conduct disorder, anxiety, and depression each require targeted intervention beyond what ADHD treatment provides.

References

  • Barkley, R.A. (Ed.) (2024). Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment (4th ed.). Guilford Press.
  • MTA Cooperative Group (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 56(12), 1073-1086.
  • PATS Study Group (2006). Short-term effects of methylphenidate in preschool children with ADHD. Journal of the American Academy of Child & Adolescent Psychiatry, 45(11), 1284-1293.